Nasal vaccine for treating, preventing Alzheimer's disease to be tested in Boston trial

"It's exciting that after 20 years of preclinical work, we can finally take a key step forward toward clinical translation and conduct this landmark first human trial," said Howard L. Weiner, the Ann Romney Center for Neurologic Diseases' co-director.